Ensysce Accounts Payable vs Current Deferred Revenue Analysis

ENSC Stock

USD 5.39 0.14 2.67%

Ensysce Biosciences financial indicator trend analysis is much more than just examining Ensysce Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ensysce Biosciences is a good investment. Please check the relationship between Ensysce Biosciences Accounts Payable and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

Accounts Payable vs Current Deferred Revenue

Accounts Payable vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ensysce Biosciences Accounts Payable account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Ensysce Biosciences' Accounts Payable and Current Deferred Revenue is 0.79. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Ensysce Biosciences, assuming nothing else is changed. The correlation between historical values of Ensysce Biosciences' Accounts Payable and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Ensysce Biosciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Accounts Payable i.e., Ensysce Biosciences' Accounts Payable and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.79

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Ensysce Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Ensysce Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Ensysce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ensysce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.At present, Ensysce Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.22, whereas Issuance Of Capital Stock is forecasted to decline to about 8.5 M.

	2024	2025 (projected)
Interest Income	98.6K	93.6K
Tax Provision	281.2K	373.2K

Interest Income Tax Provision

Ensysce Biosciences fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Net Tangible Assets	Warrants	Net Debt	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity
Total Assets		-0.77	0.88	0.96	-0.2	0.88	0.88	0.79	1.0	-0.97	-0.1	0.77	1.0	-0.35	1.0	0.75	-0.76	-0.8	1.0	0.32	-0.3	-1.0	1.0	0.73	-0.73	-0.94
Total Current Liabilities	-0.77		-0.71	-0.7	0.71	-0.75	-0.74	-0.72	-0.79	0.67	0.7	-0.65	-0.79	0.78	-0.79	-0.48	0.68	0.4	-0.79	-0.77	0.68	0.76	-0.78	-0.25	0.92	0.73
Total Stockholder Equity	0.88	-0.71		0.85	-0.2	0.76	0.76	0.87	0.88	-0.85	-0.13	0.89	0.88	-0.32	0.89	0.64	-0.67	-0.69	0.89	0.32	-0.3	-0.88	0.89	0.62	-0.67	-0.82
Retained Earnings	0.96	-0.7	0.85		-0.19	0.84	0.84	0.75	0.96	-0.98	-0.04	0.73	0.96	-0.32	0.97	0.75	-0.58	-0.83	0.96	0.27	-0.1	-0.97	0.96	0.85	-0.76	-0.93
Cash	-0.2	0.71	-0.2	-0.19		-0.16	-0.14	-0.16	-0.23	0.11	0.93	-0.09	-0.23	0.67	-0.24	0.04	0.06	-0.23	-0.23	-0.97	0.57	0.2	-0.25	0.24	0.76	0.15
Other Assets	0.88	-0.75	0.76	0.84	-0.16		1.0	0.92	0.88	-0.85	-0.19	0.88	0.89	-0.61	0.89	0.76	-0.75	-0.71	0.89	0.31	-0.28	-0.87	0.85	0.61	-0.66	-0.97
Cash And Short Term Investments	0.88	-0.74	0.76	0.84	-0.14	1.0		0.91	0.88	-0.85	-0.16	0.87	0.89	-0.59	0.89	0.76	-0.75	-0.72	0.88	0.28	-0.27	-0.87	0.85	0.62	-0.65	-0.97
Common Stock Shares Outstanding	0.79	-0.72	0.87	0.75	-0.16	0.92	0.91		0.8	-0.75	-0.23	0.99	0.8	-0.6	0.81	0.65	-0.72	-0.64	0.8	0.31	-0.32	-0.79	0.77	0.51	-0.62	-0.88
Short Term Investments	1.0	-0.79	0.88	0.96	-0.23	0.88	0.88	0.8		-0.97	-0.13	0.77	1.0	-0.38	1.0	0.75	-0.76	-0.79	1.0	0.34	-0.32	-1.0	1.0	0.72	-0.75	-0.94
Capital Surpluse	-0.97	0.67	-0.85	-0.98	0.11	-0.85	-0.85	-0.75	-0.97		-0.04	-0.74	-0.97	0.25	-0.97	-0.84	0.62	0.84	-0.97	-0.2	0.09	0.98	-0.96	-0.85	0.69	0.94
Total Liab	-0.1	0.7	-0.13	-0.04	0.93	-0.19	-0.16	-0.23	-0.13	-0.04		-0.14	-0.13	0.81	-0.13	0.15	0.18	-0.28	-0.13	-0.92	0.72	0.08	-0.13	0.43	0.64	0.1
Total Current Assets	0.77	-0.65	0.89	0.73	-0.09	0.88	0.87	0.99	0.77	-0.74	-0.14		0.78	-0.52	0.78	0.67	-0.66	-0.63	0.78	0.24	-0.23	-0.77	0.74	0.54	-0.56	-0.86
Common Stock	1.0	-0.79	0.88	0.96	-0.23	0.89	0.89	0.8	1.0	-0.97	-0.13	0.78		-0.38	1.0	0.75	-0.76	-0.79	1.0	0.35	-0.32	-0.99	1.0	0.71	-0.75	-0.94
Other Current Liab	-0.35	0.78	-0.32	-0.32	0.67	-0.61	-0.59	-0.6	-0.38	0.25	0.81	-0.52	-0.38		-0.39	-0.19	0.41	0.13	-0.38	-0.7	0.58	0.33	-0.35	0.06	0.71	0.49
Net Tangible Assets	1.0	-0.79	0.89	0.97	-0.24	0.89	0.89	0.81	1.0	-0.97	-0.13	0.78	1.0	-0.39		0.75	-0.75	-0.79	1.0	0.35	-0.31	-0.99	1.0	0.72	-0.76	-0.95
Warrants	0.75	-0.48	0.64	0.75	0.04	0.76	0.76	0.65	0.75	-0.84	0.15	0.67	0.75	-0.19	0.75		-0.41	-0.58	0.75	0.08	0.15	-0.8	0.71	0.74	-0.48	-0.83
Net Debt	-0.76	0.68	-0.67	-0.58	0.06	-0.75	-0.75	-0.72	-0.76	0.62	0.18	-0.66	-0.76	0.41	-0.75	-0.41		0.63	-0.76	-0.21	0.69	0.72	-0.75	-0.27	0.41	0.69
Accounts Payable	-0.8	0.4	-0.69	-0.83	-0.23	-0.71	-0.72	-0.64	-0.79	0.84	-0.28	-0.63	-0.79	0.13	-0.79	-0.58	0.63		-0.79	0.19	0.02	0.79	-0.79	-0.86	0.42	0.78
Non Current Assets Total	1.0	-0.79	0.89	0.96	-0.23	0.89	0.88	0.8	1.0	-0.97	-0.13	0.78	1.0	-0.38	1.0	0.75	-0.76	-0.79		0.35	-0.32	-0.99	1.0	0.71	-0.75	-0.94
Non Currrent Assets Other	0.32	-0.77	0.32	0.27	-0.97	0.31	0.28	0.31	0.34	-0.2	-0.92	0.24	0.35	-0.7	0.35	0.08	-0.21	0.19	0.35		-0.62	-0.31	0.35	-0.22	-0.77	-0.27
Net Receivables	-0.3	0.68	-0.3	-0.1	0.57	-0.28	-0.27	-0.32	-0.32	0.09	0.72	-0.23	-0.32	0.58	-0.31	0.15	0.69	0.02	-0.32	-0.62		0.25	-0.33	0.38	0.42	0.17
Common Stock Total Equity	-1.0	0.76	-0.88	-0.97	0.2	-0.87	-0.87	-0.79	-1.0	0.98	0.08	-0.77	-0.99	0.33	-0.99	-0.8	0.72	0.79	-0.99	-0.31	0.25		-0.99	-0.75	0.73	0.94
Retained Earnings Total Equity	1.0	-0.78	0.89	0.96	-0.25	0.85	0.85	0.77	1.0	-0.96	-0.13	0.74	1.0	-0.35	1.0	0.71	-0.75	-0.79	1.0	0.35	-0.33	-0.99		0.71	-0.75	-0.91
Non Current Liabilities Total	0.73	-0.25	0.62	0.85	0.24	0.61	0.62	0.51	0.72	-0.85	0.43	0.54	0.71	0.06	0.72	0.74	-0.27	-0.86	0.71	-0.22	0.38	-0.75	0.71		-0.41	-0.75
Other Current Assets	-0.73	0.92	-0.67	-0.76	0.76	-0.66	-0.65	-0.62	-0.75	0.69	0.64	-0.56	-0.75	0.71	-0.76	-0.48	0.41	0.42	-0.75	-0.77	0.42	0.73	-0.75	-0.41		0.71
Other Stockholder Equity	-0.94	0.73	-0.82	-0.93	0.15	-0.97	-0.97	-0.88	-0.94	0.94	0.1	-0.86	-0.94	0.49	-0.95	-0.83	0.69	0.78	-0.94	-0.27	0.17	0.94	-0.91	-0.75	0.71

Click cells to compare fundamentals

Ensysce Biosciences Account Relationship Matchups

Ensysce Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	351.8K	16.4M	5.9M	2.7M	2.4M	2.3M
Total Current Liabilities	7.0M	16.5M	9.5M	3.3M	3.8M	6.2M
Total Stockholder Equity	(6.4M)	(8.2M)	(4.0M)	(322.9K)	(290.6K)	(276.0K)
Retained Earnings	(56.0M)	(85.8M)	(110.9M)	(121.6M)	(109.4M)	(103.9M)
Cash	194.2K	12.3M	3.1M	1.1M	1.3M	1.2M
Other Assets	5K	3.8K	754.8K	585.9K	527.3K	500.9K
Cash And Short Term Investments	194.2K	12.3M	3.1M	1.1M	1.0M	960.7K
Common Stock Shares Outstanding	68.8K	84.0K	179.9K	2.3M	2.0M	3.9M
Long Term Debt Total	566.3K	791.3K	4.4M	140.2K	161.2K	153.1K
Liabilities And Stockholders Equity	351.8K	16.4M	5.9M	2.7M	2.4M	2.3M
Capital Surpluse	2.9M	2.5M	78.0M	107.2M	123.3M	129.5M
Total Liab	7.0M	24.6M	9.9M	3.4M	3.9M	3.7M
Total Current Assets	347.9K	15.7M	5.3M	2.3M	2.1M	2.0M
Short Term Debt	4.3M	12.7M	4.3M	854.7K	982.9K	933.8K
Common Stock	1.6K	2.5K	642.0	315.0	283.5	269.33
Other Current Liab	856.0K	3.4M	2.3M	542.3K	623.6K	592.4K
Net Debt	4.1M	483.4K	1.3M	(268.9K)	(309.2K)	(293.8K)
Accounts Payable	1.7M	301.1K	2.9M	1.9M	2.2M	1.4M
Non Current Assets Total	3.9K	754.8K	585.9K	419.2K	377.3K	358.4K
Non Currrent Assets Other	3.8K	(24.7B)	558.7K	419.2K	377.3K	396.2K
Non Current Liabilities Total	6.8M	8.1M	450.5K	26.4K	23.7K	22.6K
Other Current Assets	153.7K	3.4M	2.2M	1.1M	1.2M	1.3M
Other Stockholder Equity	49.5M	77.7M	106.9M	121.2M	139.4M	146.4M
Short Long Term Debt Total	5.1M	17.2M	4.4M	854.7K	769.2K	730.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:

How To Invest In Ensysce

Details

Is Ensysce Stock a good investment?

Details

What is Ensysce Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(29.10)

Revenue Per Share

10.216

Quarterly Revenue Growth

6.853

Return On Assets

(0.63)

Return On Equity

(2.05)

The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ensysce Accounts Payable vs Current Deferred Revenue Analysis

Accounts Payable vs Current Deferred Revenue

Accounts Payable vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Accounts Payable

Current Deferred Revenue

Ensysce Biosciences fundamental ratios Correlations

Ensysce Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ensysce Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Total Assets
Common Stock	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Retained Earnings Total Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Other Assets

Common Stock Total Equity	- 1.0	Short Term Investments
Common Stock Total Equity	- 1.0	Total Assets
Retained Earnings Total Equity	- 0.99	Common Stock Total Equity
Common Stock Total Equity	- 0.99	Non Current Assets Total
Common Stock Total Equity	- 0.99	Net Tangible Assets
Common Stock Total Equity	- 0.99	Common Stock